Granahan Investment Management, LLC Kezar Life Sciences, Inc. Transaction History

Granahan Investment Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.72 - $1.15 $326,604 - $521,659	453,617 Added 31.23%	1,906,175 $1.81 Million
Q3 2023 Nov 14, 2023	SELL	$1.08 - $2.54 $482,177 - $1.13 Million	-446,461 Reduced 23.51%	1,452,558 $1.73 Million
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $1.8 Million - $2.38 Million	777,683 Added 69.35%	1,899,019 $4.65 Million
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $1.35 Million - $3.15 Million	430,955 Added 62.42%	1,121,336 $3.51 Million
Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $1.55 Million - $2.14 Million	242,963 Added 54.3%	690,381 $4.86 Million
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $1.37 Million - $1.84 Million	171,254 Added 62.01%	447,418 $3.85 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $487,673 - $1.82 Million	106,479 Added 62.75%	276,164 $2.28 Million
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $657,102 - $979,243	53,423 Added 45.95%	169,685 $2.82 Million
Q4 2021 Feb 14, 2022	BUY	$7.44 - $16.72 $864,989 - $1.94 Million	116,262 New	116,262 $1.94 Million

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.